CompFox AI Summary
This multi-district litigation addresses defendant Allergan's alleged anticompetitive efforts to delay FDA approval of generic versions of its dry-eye medication, Restasis®. Plaintiffs, comprising Direct Purchaser Plaintiffs and End-Payor Plaintiffs, contend Allergan engaged in various unlawful strategies, including filing sham citizen petitions, defrauding the USPTO to secure second-wave patents, wrongfully listing these patents, initiating sham patent infringement lawsuits, and transferring patents to a Native American tribe to invoke sovereign immunity. Allergan moved to dismiss the consolidated complaints, asserting that plaintiffs failed to plausibly allege that its actions caused any delay in generic market entry. The court, however, denied Allergan's motion, concluding that the plaintiffs had adequately pleaded that Allergan's aggressive and persistent tactics could have effectively delayed competition.
1199seiu Nat'l Benefit Fund v. Allergan, Inc. (In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litig.) is a workers' compensation case decided in District Court, E.D. New York. This case addresses legal issues related to compensation claims, benefits, and court rulings.
It is commonly referenced in legal research involving workers' compensation laws in District Court, E.D. New York.
Full Decision Text1 Pages
This multi-district litigation addresses defendant Allergan's alleged anticompetitive efforts to delay FDA approval of generic versions of its dry-eye medication, Restasis®. Plaintiffs, comprising Direct Purchaser Plaintiffs and End-Payor Plaintiffs, contend Allergan engaged in various unlawful strategies, including filing sham citizen petitions, defrauding the USPTO to secure "second-wave" patents, wrongfully listing these patents, initiating sham patent infringement lawsuits, and transferring patents to a Native American tribe to invoke sovereign immunity. Allergan moved to dismiss the consolidated complaints, asserting that plaintiffs failed to plausibly allege that its actions caused any delay in generic market entry. The court, however, denied Allergan's motion, concluding that the plaintiffs had adequately pleaded that Allergan's aggressive and persistent tactics could have effectively delayed competition.
Read the full decision
Join + legal professionals. Create a free account to access the complete text of this decision and search our entire database.